Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Course of Symptoms as assessed in 21 ovarian cancer patients with the ovarian cancer-specific module (OV-28) of the EORTC Quality of Life core questionnaire

From: Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy

EORTC QLQ-OV28c
  Baselinea CT 3b CT 6 AC1b AC2 constant term/
beta coefficient
Abdominal Symptoms (AS) 41.9 (28.1) 21.8 29.2 20.5 13.5
(21.7)
36.8/-3.0 t = -2.72; p = 0.009
Peripheral Neuropathy (PN) 32.8 (26.2) 37.7 39.2 37.7 23.1 (26.1) 35.3/-0.5 t = -0.39; p = 0.697
Other Chemotherapy-related Side Effects (CSE) 30.2 (33.8) 29.3 29.8 23.0 1.6
(2.7)
42.4/-5.7 t = -5.97; p < 0.001
Hormonal/menopausal Symptoms (HS) 34.1 (35.1) 22.2 26.5 31.5 22.2 (31.2) 30.2/-0.8 t = -0.55; p = 0.587
Body Image (BI) 73.0 (33.1) 74.5 84.3 75.0 77.8 (25.0) 74.2/0.8 t = 0.68; p = 0.502
Attitudes towards Disease
and Treatment (AT)
26.1 (22.6) 39.5 56.9 53.7 66.7 (24.6) 27.1/5.4 t = 5.30; p < 0.001
Sexual Functioning (SF) 47.9 (21.9) 64.3 48.8 57.3 57.4 (12.8) 48.9/1.0 n = 8
  1. a Baseline (CT1)
  2. b CT chemotherapy cycle, AC aftercare
  3. c Reference values (ovarian cancer patients, all stages) [54]: AS = 21.9 (22.1), PN = 17.1 (27.2), CSE = 19.5 (20.5), HS = 25.8 (30.3), BI = 22.2 (27.4), AT = 42.3 (30.6)